T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies

Available for licensing are methods to generate T cells responsive to multiple polyomaviruses. The resulting T cell populations could be useful in treating immunosuppressed individuals with polyomavirus infections or polyomavirus-associated pathologies such as Merkel cell carcinoma (MCC), polyomavirus-associated nephropathy (PVAN), hemorrhagic cystitis, progressive multifocal leukoencephalopathy (PML), and trichodysplasia spinulosa (TS). The methods could also be used to restore polyomavirus-specific immunity in immunocompromised individuals.

Potential Commercial Applications:		Competitive Advantages:
Immunotherapy for immunosuppressed individuals with polyomavirus-associated pathologies.		Methods allow development of polyomavirus antigen-specific T cells.

Development Stage:

• Early-stage
• In vitro data available

Related Invention(s):
E-168-2011-0
E-549-2013-0


Inventors:

Christopher Buck (NCI)  ➽ more inventions...

John Barrett (NHLBI)  ➽ more inventions...

Dhanalakshmi Chinnasamy (NHLBI)  ➽ more inventions...

Pawel Muranski (NHLBI)  ➽ more inventions...


Intellectual Property:
PCT Application No. PCT/US2015/059021
US Application No. 62/075,726

Collaboration Opportunity:
The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize methods to generate T cells responsive to multiple polyomaviruses. For collaboration opportunities, please contact Dr. Vincent Kolesnitchenko at kolesniv@nhlbi.nih.gov.


Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-166-2014-0
Updated: Sep 12, 2017